The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies (2004)

Peer-Reviewed Study · Graeme Morgan; Robyn Ward; Michael Barton · December 2004

Graeme Morgan et al., 2004-12: Modelling study of 22 adult malignancies estimating that curative and adjuvant cytotoxic chemotherapy accounts for 2.3% of 5-year survival in Australia and 2.1% in the USA. Methods: RCTs and meta-analyses published 1 Jan 1990 to 1 Jan 2004, incidence from 1998 AIHW and SEER data, benefit weighted by the subgroup likely to receive chemo.

The overall contribution of curative and adjuvant cytotoxic chemotherapy to 5-year survival in adults was estimated to be 2.3% in Australia and 2.1% in the USA.

Abstract, Results

Graeme Morgan et al., 2004-12: Modelling study of 22 adult malignancies estimating that curative and adjuvant cytotoxic chemotherapy accounts for 2.3% of 5-year survival in Australia and 2.1% in the USA. Methods: RCTs and meta-analyses published 1 Jan 1990 to 1 Jan 2004, incidence from 1998 AIHW and SEER data, benefit weighted by the subgroup likely to receive chemo. Funder: none declared in the article; no disclosure statement on the record. Comparator: literature synthesis, not a trial. Exclusions stated in Methods: small-number cancers (gall bladder, pleura, eye, bone, penis, placenta) and acute/chronic leukaemia (2% of cases), the latter partly because such patients are treated by haematologists; the 22 malignancies cover 90% of Australian cases in 1998. Authors state they 'erred on the side of over-estimating the benefit'. The paper's own per-site numbers assume benefit only in subgroups (e.g. colon cancer: Duke's C only, 5% absolute). Journal page (clinicaloncologyonline.net) currently served a Cloudflare challenge; abstract verified on the PubMed record. Study type: review.